Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
1 hedge funds and large institutions have $3.55K invested in Day One Biopharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 203 closing their positions.
84.09% less ownership
Funds ownership: 84.09% → 0% (-84%)
100% less funds holding
Funds holding: 207 → 1 (-206)
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
100% less capital invested
Capital invested by funds: $1.85B → $3.55K (-$1.85B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 203
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$151M |
| 2 |
GCL
Glazer Capital LLC
New York
|
-$100M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$88.6M |
| 4 |
KC
Kryger Capital
London,
United Kingdom
|
-$83.5M |
| 5 |
DM
Deerfield Management
New York
|
-$79.8M |
DAWN Hedge Fund Activity: Q2 2026 in Review
1 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q2 2026, worth a combined $3.55K — down 100% from $1.85B a quarter earlier.
Sellers outnumbered buyers: 203 funds closed out of DAWN and 0 opened new positions — a net loss of 203 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $151M sold.
- 1 institutional investor held Day One Biopharmaceuticals (DAWN) as of Q2 2026, down from 207 in Q1 2026.
- Funds reported $3.55K of Day One Biopharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
- 0 funds opened new Day One Biopharmaceuticals positions in Q2 2026 and 203 closed out, a net change of -203 holders.
- The largest Day One Biopharmaceuticals seller in Q2 2026 was BlackRock, an estimated $151M sold.
Based on aggregated 13F filings for Q2 2026.